Results 161 to 170 of about 19,469 (260)

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Neuromuscular Blocking Agents in Anesthesia: A Narrative Review of Contemporary Challenges and Reversal Approaches. [PDF]

J Clin Med
Radkowski P, Jutrzenka M, Szewczyk M, Witkowska A, Muża M, Onichimowski D, Grabarczyk Ł.   +6 more
europepmc   +1 more source

Protocol‐Based Management of Medication Confounders in Brain Death Determination: A Multi‐Institutional Review

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 7, July 2026.
ABSTRACT Background Determination of death by neurologic criteria (DNC) relies on clinical examination, provided no confounding conditions affect reliability. Current guidelines require patients to be free of confounders before neurologic testing but do not specify how these confounders should be assessed or managed.
Alexander Nixon, Jeffrey Mucksavage, Chris Morrison, Nicholas G. Panos, Katleen Chester, Sherif Hanafy Mahmoud, Devin Holden, Casey C. May   +7 more
wiley   +1 more source

Use of Neuromuscular Blocking Agents in Elderly Patients: A Narrative Review in Geriatric Medicine. [PDF]

Int J Gen Med
Radkowski P, Szewczyk M, Dabdoub T, Murthy R, Grabarczyk Ł.   +4 more
europepmc   +1 more source

Osteoarthritis: Epidemiology, Diagnosis, and Treatment

MedComm, Volume 7, Issue 7, July 2026.
Osteoarthritis (OA) is a multifactorial degenerative joint disease and a leading cause of disability worldwide. This graphical abstract summarizes the epidemiology, diagnostic strategies, and therapeutic approaches of OA. OA development is driven by aging, metabolic dysregulation, and mechanical stress, leading to progressive joint degeneration ...
Qin Ru, Dongliang Yuan, Shide Jiang, Xiaoxuan Zhao, Xu Liu, Yusheng Li, Shuguang Liu, Yuxiang Wu   +7 more
wiley   +1 more source

Age-Specific Pharmacology of Neuromuscular Blocking Agents: A Comprehensive Review. [PDF]

Med Sci Monit
Radkowski P, Kowalczyk K, Łęczycka A, Oniszczuk H, Grabarczyk Ł.   +4 more
europepmc   +1 more source

Flexible organic frameworks sequester neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo. [PDF]

Chem Sci, 2022
Wu Y, Liu YY, Liu HK, Yu SB, Lin F, Zhou W, Wang H, Zhang DW, Li ZT, Ma D.   +9 more
europepmc   +1 more source

Neuromuscular Block and Blocking Agents in 2018

Turkish Journal of Anesthesia and Reanimation, 2018
openaire   +2 more sources

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, Volume 46, Issue 4, Page 1173-1229, July 2026.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Development of the neuromuscular junction and neuromuscular blocking agents in neonates, infants and children: A narrative review. [PDF]

Eur J Anaesthesiol
Saldien V, Veyckemans F, Hansen TG.
europepmc   +1 more source